Kazia Therapeutics Unveils Promising Preclinical Results for Paxalisib Against Colorectal Cancer
Kazia Therapeutics, a Sydney-based biotechnology firm listed on NASDAQ under the symbol KZIA, has recently released compelling preclinical data concerning its anti-cancer drug, Paxalisib. This innovative compound has demonstrated remarkable efficacy in reducing tumor burdens in microsatellite stable (MSS) and proficient mismatch repair (pMMR) colorectal cancer models, specifically highlighting its ability to enhance responses to existing immun therapies. In one study, Paxalisib alone yielded a significant 52% reduction in tumor volume (p=0.035), while when combined with the established immunotherapy pembrolizumab, it resulted in an additional 50% decrease (p=0.022).
The research further indicates that Paxalisib was well tolerated by participants, showing no signs of treatment-related toxicity. This is particularly encouraging given the urgent need for effective treatments against colorectal cancer, which is a leading cause of cancer-related mortality worldwide. Much of this challenge lies in the resistance often observed with current immunotherapies in treating colorectal cancer, especially among the 85-90% of patients with MSS/pMMR type. Existing studies have shown that, unlike their microsatellite instability high (MSI-H) counterparts, the MSS/pMMR tumors do not respond well to checkpoint inhibitors, making Paxalisib's approach potentially groundbreaking.
Kazia Therapeutics is poised to further investigate Paxalisib's capabilities with plans for a Phase 2 clinical trial that includes a five-arm study. This will evaluate Paxalisib, both as a standalone treatment and in combination with pembrolizumab, against standard care for pre-treated MSS/pMMR metastatic colorectal cancer. The study will prioritize assessing safety and tolerability while also examining progression-free survival, overall response rates, and overall survival as secondary endpoints. Patient enrollment is anticipated to begin in early 2027, with the aim of completing recruitment by the end of the same year.
Dr. Sudha Rao, Chief Scientific Officer at Kazia, expressed optimism regarding the findings. The innovative research suggests that Paxalisib may effectively reprogram the tumor microenvironment, thereby enhancing the visibility of cancer cells to the immune system. This shift from being immunotherapy-resistant to becoming responsive is crucial in developing novel treatment protocols for colorectal cancer.
In addition to Paxalisib, Kazia is actively advancing various clinical programs targeting other forms of cancer. This includes a next-generation biomarker program designed to elucidate the molecular and immune characteristics associated with responses to Paxalisib, allowing for refined patient selection and individual treatment strategies. This program is expected to improve predictions of treatment outcomes and develop tailored biomarker strategies critical for the drug development process.
The backdrop of Kazia's research is fueled by the rising incidence of colorectal cancer, particularly noted among younger adults. With declining survival rates among patients with this condition, Kazia Therapeutics positions itself at the forefront of potentially transforming cancer treatment landscapes through its innovative and targeted therapeutic strategies.
With a history of delivering promising data in various oncology domains, Kazia Therapeutics remains dedicated to addressing the unmet medical needs of cancer patients. Both Paxalisib's investigational status and its strategic clinical trial advancements mark significant steps in the ongoing quest to conquer cancer resistance and improve patient outcomes internationally.
The research further indicates that Paxalisib was well tolerated by participants, showing no signs of treatment-related toxicity. This is particularly encouraging given the urgent need for effective treatments against colorectal cancer, which is a leading cause of cancer-related mortality worldwide. Much of this challenge lies in the resistance often observed with current immunotherapies in treating colorectal cancer, especially among the 85-90% of patients with MSS/pMMR type. Existing studies have shown that, unlike their microsatellite instability high (MSI-H) counterparts, the MSS/pMMR tumors do not respond well to checkpoint inhibitors, making Paxalisib's approach potentially groundbreaking.
Kazia Therapeutics is poised to further investigate Paxalisib's capabilities with plans for a Phase 2 clinical trial that includes a five-arm study. This will evaluate Paxalisib, both as a standalone treatment and in combination with pembrolizumab, against standard care for pre-treated MSS/pMMR metastatic colorectal cancer. The study will prioritize assessing safety and tolerability while also examining progression-free survival, overall response rates, and overall survival as secondary endpoints. Patient enrollment is anticipated to begin in early 2027, with the aim of completing recruitment by the end of the same year.
Dr. Sudha Rao, Chief Scientific Officer at Kazia, expressed optimism regarding the findings. The innovative research suggests that Paxalisib may effectively reprogram the tumor microenvironment, thereby enhancing the visibility of cancer cells to the immune system. This shift from being immunotherapy-resistant to becoming responsive is crucial in developing novel treatment protocols for colorectal cancer.
In addition to Paxalisib, Kazia is actively advancing various clinical programs targeting other forms of cancer. This includes a next-generation biomarker program designed to elucidate the molecular and immune characteristics associated with responses to Paxalisib, allowing for refined patient selection and individual treatment strategies. This program is expected to improve predictions of treatment outcomes and develop tailored biomarker strategies critical for the drug development process.
The backdrop of Kazia's research is fueled by the rising incidence of colorectal cancer, particularly noted among younger adults. With declining survival rates among patients with this condition, Kazia Therapeutics positions itself at the forefront of potentially transforming cancer treatment landscapes through its innovative and targeted therapeutic strategies.
With a history of delivering promising data in various oncology domains, Kazia Therapeutics remains dedicated to addressing the unmet medical needs of cancer patients. Both Paxalisib's investigational status and its strategic clinical trial advancements mark significant steps in the ongoing quest to conquer cancer resistance and improve patient outcomes internationally.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.